看之前记得先点个关注,欢迎投稿共创。药圈观察局,最新观察:本文为共创内容,作者:#药圈观察局1组2月23日,吉利德科学宣布以每股115美元现金加每股5美元或有价值权(CVR)的全现金方式,收购临床阶段生物技术公司Arcellx,交易隐含股权价值高达78亿美元。早在2022年12月,吉利德旗下专注于细胞疗法的子公司Kite Pharma,便以高达41.25亿美元(2.25亿美元首付款+最高39...
Source Link看之前记得先点个关注,欢迎投稿共创。药圈观察局,最新观察:本文为共创内容,作者:#药圈观察局1组2月23日,吉利德科学宣布以每股115美元现金加每股5美元或有价值权(CVR)的全现金方式,收购临床阶段生物技术公司Arcellx,交易隐含股权价值高达78亿美元。早在2022年12月,吉利德旗下专注于细胞疗法的子公司Kite Pharma,便以高达41.25亿美元(2.25亿美元首付款+最高39...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.